ReviewFrontiers in cellular and infection microbiology2021
Can We Improve Antifungal Susceptibility Testing?
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Rapid antifungal susceptibility testing from positive blood cultures using direct gradient diffusion: a prospective study.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Observational
- [Rapid detection of fluconazole resistance inNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Global perspective on gaps in fungal diagnostics in low-resource settings: WHO landscape analysis and research priorities for invasive fungal diseases.The Lancet. Microbe · 2026Review
- Towards accurate genomic detection of fungal antimicrobial resistance: progress in fungal resistance databases and bioinformatic tools.Microbial genomics · 2026Review
- A Pragmatic Strategy for Improving Diagnosis of Invasive Candidiasis in UK and Ireland ICUs.Journal of fungi (Basel, Switzerland) · 2025Article
- First Isolation of a Multi-azole-Resistant Aspergillus fumigatus cyp51A TRMycopathologia · 2025Article
- Comparative evaluation of antifungal susceptibility testing methods of invasive Candida species and detection of FKS genes mutations in caspofungin intermediate and resistant isolates.BMC infectious diseases · 2025Article
- Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing ofAntibiotics (Basel, Switzerland) · 2024Article
- Utilizing Next-Generation Sequencing: Advancements in the Diagnosis of Fungal Infections.Diagnostics (Basel, Switzerland) · 2024Review
- What do We Know about Cryptic Aspergillosis?Microorganisms · 2024Review
- Evaluation of the Vitek 2 system for antifungal susceptibility testing ofJournal of clinical microbiology · 2024Article
- Article
- The Influence of Medium Composition on EUCAST and Etest Antifungal Susceptibility Testing.Journal of fungi (Basel, Switzerland) · 2023Article
- MALDI-TOF MS: A Quick Method to Detect the Susceptibility ofMicroorganisms · 2023Article
- Aspergillus Species Causing Invasive Fungal Disease in Queensland, Australia.Mycopathologia · 2023Article
- A Practical Guide to Antifungal Susceptibility Testing.Journal of the Pediatric Infectious Diseases Society · 2023Article
- Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics ofJournal of fungi (Basel, Switzerland) · 2023Review
- Current Landscape of Methods to Evaluate Antimicrobial Activity of Natural Extracts.Molecules (Basel, Switzerland) · 2023Review
- The challenges of the genome-based identification of antifungal resistance in the clinical routine.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic antifungal agents are increasingly used for prevention or treatment of invasive fungal infections, whose prognosis remains poor. At the same time, emergence of resistant or even multi-resistant strains is of concern as the antifungal arsenal is limited. Antifungal susceptibility testing (AFST) is therefore of key importance for patient management and antifungal stewardship. Current AFST methods, including reference and commercial types, are based on growth inhibition in the presence of an antifungal, in liquid or solid media. They usually enable Minimal Inhibitory Concentrations (MIC) to be determined with direct clinical application. However, they are limited by a high turnaround time (TAT). Several innovative methods are currently under development to improve AFST. Techniques based on MALDI-TOF are promising with short TAT, but still need extensive clinical validation. Flow cytometry and computed imaging techniques detecting cellular responses to antifungal stress other than growth inhibition are also of interest. Finally, molecular detection of mutations associated with antifungal resistance is an intriguing alternative to standard AFST, already used in routine microbiology labs for detection of azole resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.